A clinical trial involving oxytocin has been updated as of September 4, 2026. The study, titled "Open, Randomized Feasibility Trial on the Safety and Performance of the INGA Catheter for Labor Induction," is registered under identifier NCT07214948.
According to its listing on ClinicalTrials.gov, the trial's current status is TERMINATED. The trial phase is listed as not applicable (NA), consistent with its designation as a feasibility study focused on device safety and performance rather than a traditional drug phase trial.
No results, efficacy data, or safety findings were provided in this update. The termination status is a factual designation reflecting the trial's current registered state and does not, by itself, indicate the reason for stopping or any outcome regarding the INGA Catheter or oxytocin's role in labor induction procedures studied.
Readers seeking further detail on the trial's design, enrollment, or any future updates should consult the official trial registration directly. This brief reflects only the information provided in the trial update dated September 4, 2026, without additional interpretation of results or implications for oxytocin's established use in labor induction.
For more background on oxytocin as a compound, see the linked overview page.